Adalid Sciences, a startup building next-generation lipid nanoparticles for gene delivery, has secured $215K in seed funding. The company's technology moves beyond traditional LNP designs by focusing on fully tunable compositions. This includes the design of ionizable lipids with customizable properties and advanced outer shell architectures, enabling tailored solutions for specific therapeutic applications like multi-cargo delivery and prolonged blood circulation, without relying on PEG-lipid.


















